LeMaitre Vascular, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2021
February 24, 2022 at 04:16 pm EST
Share
LeMaitre Vascular, Inc. reported earnings results for the fourth quarter and full year ended December 31, 2021. For the fourth quarter, the company reported sales was USD 39.5 million compared to USD 37.55 million a year ago. Net income was USD 6.18 million compared to USD 7.03 million a year ago. Basic earnings per share from continuing operations was USD 0.28 compared to USD 0.35 a year ago. Diluted earnings per share from continuing operations was USD 0.28 compared to USD 0.34 a year ago.
For the full year, sales was USD 154.42 million compared to USD 129.37 million a year ago. Net income was USD 26.91 million compared to USD 21.22 million a year ago. Basic earnings per share from continuing operations was USD 1.27 compared to USD 1.05 a year ago. Diluted earnings per share from continuing operations was USD 1.25 compared to USD 1.04 a year ago.
LeMaitre Vascular, Inc. is a provider of devices, implants, and services for the treatment of peripheral vascular disease. The Company develops, manufactures, and markets disposable and implantable vascular devices to address the needs of its core customer, the vascular surgeon. Its portfolio of product lines is primarily used to treat vascular disease, of which most are used in open vascular surgery and dialysis access. It also offers human vascular and cardiac tissue cryopreservation services. Its principal product lines include anastomotic clips, biologic vascular and dialysis grafts, biologic vascular and cardiac patches, carotid shunts, embolectomy catheters, occlusion catheters, radiopaque marking tape, synthetic vascular and dialysis grafts, and valvulotomes. The Companyâs principal biologic offerings include vascular and cardiac patches as well as vascular and dialysis grafts. The Company sells its products and services primarily through a direct sales force.